Glycation alter serum albumin binding of valsartan and nateglinide when studied contemporarily

References

• Dunn, C. J.; Faulds, D. Nateglinide. Drugs 2000, 60, 607–615.
   PubMed Web of Science ®Google Scholar
• Ridker, P. M.; Danielson, E.; Rifai, N.; Glynn, R. J. Val-MARC Investigators. Valsartan, Blood Pressure Reduction, and C-reactive Protein: Primary Report of the Val-MARC Trial. Hypertension 2006, 48, 73–79.
   PubMed Web of Science ®Google Scholar
• Nash, D. T.; McNamara, M. C. Valsartan Combination Therapy in the Management of Hypertension—Patient Perspectives and Clinical Utility. Integr. Blood Press Control 2009, 2, 39–54.
   PubMedGoogle Scholar
• Julius, S.; Kjeldsen, S. E.; Weber, M.; Brunner, H. R.; Ekman, S.; Hansson, L.; Hua, T.; Laragh, J.; McInnes, G. T.; Mitchell, L.; Plat, F.; Schork, A.; Smith, B.; Zanchetti, A For the VALUE trial group. Outcomes in Hypertensive Patients at High Cardiovascular Risk Treated with Regimens based on Valsartan or Amlodipine: The VALUE Randomized Trial. Lancet 2004, 363, 2022–2031.
   PubMed Web of Science ®Google Scholar
• Kjeldsen, S. E.; McInnes, G. T.; Mancia, G.; Hua, T. A.; Julius, S.; Weber, M. A.; Coca, A.; Girerd, X.; Jamerson, K.; Larochelle, P.; Macdonald, T.; Schmieder, R. E.; Schork, M. A.; Viskoper, R.; Widimský, J.; Zanchetti, A. For the VALUE trial investigators. Progressive Effects of Valsartan Compared with Amlodipine in Prevention of Diabetes According to Categories of Diabetogenic Risk in Hypertensive Patients: The VALUE Trial. Blood Press 2008, 17, 170–177.
   PubMed Web of Science ®Google Scholar
• Wong, Y. W.; Thomas, L.; Sun, J. L.; McMurray, J. J. V.; Krum, H.; Hernandez, A. F.; Rutten, G. E. H. M.; Leiter, L. A.; Standl, E.; Haffner, S. M.; Mazzone, T.; Martinez, F. A.; Tognoni, G.; Giles, T.; Califf, R. M. Predictors of Incident Heart Failure Hospitalizations Among Patients with Impaired Glucose Tolerance. Circ. Heart Failure 2013, 6, 203–210.
   PubMed Web of Science ®Google Scholar
• The NAVIGATOR Study Group. Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. N Engl. J. Med. 2010, 362, 1477–1490.
   PubMed Web of Science ®Google Scholar
• Califf, R. M.; Holman, R. R.; Farkouh, M. Valsartan Reduced Diabetes but not CV Events in Patients with Impaired Glucose Tolerance and CV Risk Factors. ACP J. Club 2010, 152, 9–10.
   Google Scholar
• Benet, L. Z.; Hoener, B. A. Commentary: Changes in Plasma Protein Binding have Little Clinical Relevance. Clin. Pharm. Ther. 2002, 71, 115–121.
   PubMed Web of Science ®Google Scholar
• Cohen, L. H. Plasma Protein-binding Methods in Drug Discovery. In Optimization in Drug Discovery: In Vitro Methods; Yan, Z., Caldwell, G. W., Eds.; 1st ed; Humana Press Inc.: Totowa, NJ, 2004, 111–122 pp.
   Google Scholar
• Tsai, T. H. Assaying Protein Unbound Drugs using Microdialysis Techniques. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2003, 797, 161–173.
   PubMed Web of Science ®Google Scholar
• Mehvar, R. Role of Protein Binding in Pharmacokinetics. Am. J. Pharm. Edu. 2005, 69, 1–10.
   Google Scholar
• Sansom, L. N.; Evans, A. M. What is the True Clinical Significance of Plasma Protein Binding Displacement Interactions? Drug Saf. 1995, 12, 227–233.
   PubMed Web of Science ®Google Scholar
• Smith, D. A.; Di, L.; Kerns, E. H. The Effect of Plasma Protein Binding on In Vivo Efficacy: Misconceptions in Drug Discovery. Nat. Rev. Drug Discovery 2010, 9, 929–940.
   PubMed Web of Science ®Google Scholar
• Mendez, C. M.; McClain, C. J.; Marsano, L. S. Albumin Therapy in Clinical Practice. Nutr. Clin. Pract. 2005, 20, 314–320.
   PubMedGoogle Scholar
• Rondeau, P.; Bourdon, E. The Glycation of Albumin: Structural and Functional Impacts. Biochimie 2011, 93, 645–658.
   PubMed Web of Science ®Google Scholar
• Fanali, G.; Masi, A. D.; Trezza, V.; Marino, M.; Fasano, M.; Ascenzi, P. Human Serum Albumin: From Bench to Bedside. Mol. Aspects Med. 2012, 33, 209–290.
   PubMed Web of Science ®Google Scholar
• Schleicher, E.; Deufel, T.; Wieland, O. H. Non-enzymatic Glycosylation of Human Serum Lipoproteins. Elevated ε-lysine Glycosylated Low Density Lipoproteins in Diabetic Patients. FEBS Lett. 1981, 129, 1–4.
   PubMed Web of Science ®Google Scholar
• Nagel, T.; Korthals, J. K.; Vlassara, H.; Cerami, A. An Ultra-structural Study of Chronic Sodium Cyanate Induced Neuropathy. J. Neuropath. Exp. Neuro. 1977, 143, 351–363.
   Google Scholar
• Stevens, V. J.; Rouzer, C. A.; Monnier, V. M.; Cerami, A. Diabetic Cataract Formation: Role of Glycosylation of Lens Crystallins. Proc. Natl. Acad. Sci. USA 1978, 75, 2918–2922.
   PubMed Web of Science ®Google Scholar
• Mereish, K. A.; Rosenbergs, H.; Cobby, H. Glucosylated Albumin and its Influence on Salicylate Binding. J Pharma. Sci. 1982, 71, 235–238.
   PubMed Web of Science ®Google Scholar
• Kennedy, L.; Baynes, J. W. Non-enzymatic Glycosylation and Chronic Complications of Diabetes: An Overview. Diabetologia 1984, 26, 93–98.
   PubMed Web of Science ®Google Scholar
• Vidot, J. B.; Dubourg, A. G.; Bourdon, E.; Rondeau, P. Impaired Drug-binding Capacities of In Vitro and In Vivo Glycated Albumin. Biochimie 2012, 94, 1960–1967.
   PubMed Web of Science ®Google Scholar
• Matsuda, R.; Anguizola, J.; Joseph, K. S.; Hage, D. S. High-performance Affinity Chromatography and the Analysis of Drug Interactions with Modified Proteins: Binding of Gliclazide with Glycated Human Serum Albumin. Anal. Bioanal. Chem. 2011, 401, 2811–2819.
   PubMed Web of Science ®Google Scholar
• Darban, R. A.; Shareghi, B.; Asoodeh, A.; Chamani, J. Multi-spectroscopic and Molecular Modeling Studies of Interaction Between Two Different Angiotensin I Converting Enzyme Inhibitory Peptides from Gluten Hydrolysate and Human Serum Albumin. J. Biomol. Struct. Dyn. 2016, 34, 1–15.
   PubMedGoogle Scholar
• Moghaddam, M. M.; Pirouzi, M.; Saberi, M. M.; Chamania, J. Comparison of the Binding Behavior of FCCP with HSA and HTF as Determined by Spectroscopic and Molecular Modeling Techniques. Luminescence 2014, 29, 314–331.
   PubMed Web of Science ®Google Scholar
• Ziyarat, F. P.; Asoodeh, A.; Barfeha, Z. S.; Pirouzia, M.; Chamania, J. Probing the Interaction of Lysozyme with Ciprofloxacin in the Presence of Different-sized Ag Nano-particles by Multispectroscopic Techniques and Isothermal Titration Calorimetry. J. Biomol. Struct. Dyn. 2014, 32, 613–629.
   PubMed Web of Science ®Google Scholar
• Lloyd, T. Techniques for Determining Protein Binding in Drug Discovery and Development. In ADME-Enabling Technologies in Drug Design and Development; Zhang, D., Surapaneni, S., Eds.; John Wiley & Sons Inc.: Hoboken, New Jersey, 2012; 177–187 pp.
   Google Scholar
• USFDA Draft guideline for industry on Bioanalytical method validation. US Department of Health and Human Services Food and Drug Administration (CDER & CVM): Rockville, MD, USA, 2013.
   Google Scholar
• Snyder, L. R.; Krikland, J. J.; Glajch, J. H. Practical HPLC Method Development, 2nd Ed. Wiley-Blackwell: New York, 1997.
   Google Scholar
• Monograph of Nateglinide. US Pharmacopoeia-National Formulary USP 34 NF 29. US Pharmacopeial Convention Inc.: Rockville, MD, 2011; Vol. 1, 3611–3612 pp.
   Google Scholar
• Monograph of Valsartan. Indian Pharmacopoeia. Indian Pharmaceutical Commission, Ministry of Health and Family Welfare, Government of India: Ghaziabad, 2014; Vol. 3, 7th Ed., 2951–2952 pp.
   Google Scholar
• Bunn, H. F.; Gabbay, K. H.; Gallop, P. M. The Glycosylation of Hemoglobin: Relevance to Diabetes Mellitus. Science 1978, 200, 21–27.
   PubMed Web of Science ®Google Scholar
• Califf, R. M.; Boolell, M.; Haffner, S. M.; Bethel, M. A.; McMurray, J.; Duggal, A.; Holman, R. R. Prevention of Diabetes and Cardiovascular Disease in Patients with Impaired Glucose Tolerance: Rationale and Design of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J. 2008, 156, 623–632.
   PubMed Web of Science ®Google Scholar
• Plum, A.; Mueller, L. K.; Jansen, J. A. The Effects of Selected Drugs on the In Vitro Protein Binding of Repaglinide in Human Plasma. Methods Find Exp. Clin. Pharmacol. 2000, 22, 139.
   PubMedGoogle Scholar
• Chatterjee, R.; Thomas, L.; Svetkey, L.; Brancati, F. L.; Califf, R. M.; Edelman, D. Effects of Changes in Potassium with Valsartan Use on Diabetes Risk: Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am. J. Hypertens. 2013, 26, 723–727.
   PubMed Web of Science ®Google Scholar
• Colussi, D. M.; Parisot, C. S.; Rossolino, M. L.; Brunner, L. A.; Lefevre, G. Y. Protein Binding in Plasma of Valsartan, a New Angiotensin II Receptor Antagonist. J. Clin. Pharmacol. 1997, 37, 214–221.
   PubMed Web of Science ®Google Scholar
• McLeod, J. M. Clinical Pharmacokinetics of Nateglinide. Clin. Pharmacokinet. 2004, 43, 97–120.
   PubMed Web of Science ®Google Scholar
• Carter, D. C.; Ho, J. X.; Wang, Z. Albumin Binding Sites for Evaluating Drug Interactions and Methods of Evaluating or Designing Drugs Based on their Albumin Binding Properties. United States Patent Application Publication US 2007/0043509 A1, 2007.
   Google Scholar
• Omidvar, Z.; Asoodeh, A.; Chamani, J. Studies on the Antagonistic Behavior Between Cyclophosphamide Hydrochloride and Aspirin with Human Serum Albumin: Time-resolved Fluorescence Spectroscopy and Isothermal Titration Calorimetry. J. Solution Chem. 2013, 42, 1005–1017.
   Web of Science ®Google Scholar
• Rondeau, P.; Navarra, G.; Cacciabaudo, F.; Leone, M.; Bourdon, E.; Militello, V. Thermal Aggregation of Glycated Bovine Serum Albumin. Biochim. Biophys. Acta. Biochim. Biophys. Acta 2010, 1804, 789–798.
   PubMedGoogle Scholar